OM
GNMX
Opaleye Management’s Aevi Genomic Medicine, Inc. GNMX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q2 | – | Sell |
-1,070,000
| Closed | -$1.99M | – | 53 |
|
|
2017
Q1 | $1.99M | Sell |
1,070,000
-430,000
| -29% | -$800K | 0.99% | 30 |
|
|
2016
Q4 | $7.77M | Sell |
1,500,000
-300,000
| -17% | -$1.55M | 4.58% | 4 |
|
|
2016
Q3 | $10M | Sell |
1,800,000
-150,000
| -8% | -$836K | 5.25% | 4 |
|
|
2016
Q2 | $10.8M | Buy |
1,950,000
+392,300
| +25% | +$2.18M | 7.23% | 2 |
|
|
2016
Q1 | $6.85M | Buy |
1,557,700
+167,700
| +12% | +$738K | 4.27% | 6 |
|
|
2015
Q4 | $8.37M | Buy |
1,390,000
+331,600
| +31% | +$2M | 3.5% | 5 |
|
|
2015
Q3 | $8.28M | Buy |
1,058,400
+8,400
| +0.8% | +$65.7K | 4.07% | 5 |
|
|
2015
Q2 | $6.44M | Buy |
1,050,000
+200,000
| +24% | +$1.23M | 2.56% | 18 |
|
|
2015
Q1 | $6.85M | Hold |
850,000
| – | – | 3.18% | 10 |
|
|
2014
Q4 | $4.3M | Buy |
+850,000
| New | +$4.3M | 2.17% | 18 |
|